• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在慢性肾衰竭贫血患者中通过持续皮下输注重组人生长激素刺激促红细胞生成素分泌。

Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure.

作者信息

Sohmiya M, Ishikawa K, Kato Y

机构信息

Department of Medicine, Shimane Medical University, Izumo, Japan.

出版信息

Eur J Endocrinol. 1998 Mar;138(3):302-6. doi: 10.1530/eje.0.1380302.

DOI:10.1530/eje.0.1380302
PMID:9539305
Abstract

We have investigated the effect of human GH on erythropoietin (EPO) secretion in eight anemic patients with chronic renal failure (CRF) (three males and five females, aged from 46 to 83 years). Recombinant human GH was infused subcutaneously at a flow rate of 2 microg/kg body weight per 0.1 ml/h for 72 h using a portable infusion pump. Blood samples were obtained immediately before and 2, 4, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 and 168 h after the start of GH infusion. Storage urine samples were obtained before and 24, 48 and 72 h after the start of the infusion. The mean (+/- S.E.M.) basal plasma GH levels increased from 1.9 +/- 0.3 to 18.8 +/- 0.7 microg/l during the GH infusion. Plasma IGF-I levels increased 12 h after the start of GH treatment and the mean peak values of 403.6 +/- 38.5 microg/l were obtained at 72 h. Plasma EPO levels increased 6 h after the start of GH infusion, and the peak values of 38.4 +/- 11.6 IU/l were obtained at 96 h (P < 0.05 vs basal values 24.5 +/- 7.2 IU/l). Reticulocyte counts increased from 28.7 +/- 5.2 x 10(3)/microl to 40.3 +/- 8.0 x 10(3)/l at 108 h, 43.6 +/- 9.2 x 10(3)/microl at 120 h and 41.7 +/- 7.7 x 10(3)/microl at 160 h (P < 0.05). Serum urea nitrogen decreased at 72 h (P < 0.05), whereas there was no significant change in urinary excretion of nitrogen. Hemoglobin levels were not significantly changed throughout the experimental period. These findings indicate that human GH has a stimulating effect on EPO secretion in anemic patients with CRF.

摘要

我们研究了重组人生长激素(GH)对8例慢性肾功能衰竭(CRF)贫血患者促红细胞生成素(EPO)分泌的影响(3例男性和5例女性,年龄46至83岁)。使用便携式输液泵,以每0.1ml/h 2μg/kg体重的流速皮下输注重组人生长激素72小时。在开始GH输注前以及输注开始后2、4、6、12、24、36、48、60、72、84、96、108、120和168小时采集血样。在输注开始前以及输注开始后24、48和72小时采集储存尿样。在GH输注期间,平均(±标准误)基础血浆GH水平从1.9±0.3μg/L升至18.8±0.7μg/L。GH治疗开始后12小时血浆IGF-I水平升高,在72小时时获得平均峰值403.6±38.5μg/L。GH输注开始后6小时血浆EPO水平升高,在96小时时获得峰值38.4±11.6IU/L(与基础值24.5±7.2IU/L相比,P<0.05)。网织红细胞计数在108小时时从28.7±5.2×10³/μl升至40.3±8.0×10³/μl,在120小时时为43.6±9.2×10³/μl,在160小时时为41.7±7.7×10³/μl(P<0.05)。血清尿素氮在72小时时下降(P<0.05),而尿氮排泄无显著变化。在整个实验期间血红蛋白水平无显著变化。这些发现表明,重组人生长激素对CRF贫血患者的EPO分泌有刺激作用。

相似文献

1
Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure.在慢性肾衰竭贫血患者中通过持续皮下输注重组人生长激素刺激促红细胞生成素分泌。
Eur J Endocrinol. 1998 Mar;138(3):302-6. doi: 10.1530/eje.0.1380302.
2
Effect of long-term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and haemoglobin levels in anaemic patients with adult GH deficiency.长期给予重组人生长激素(rhGH)对成年生长激素缺乏性贫血患者血浆促红细胞生成素(EPO)和血红蛋白水平的影响。
Clin Endocrinol (Oxf). 2001 Dec;55(6):749-54. doi: 10.1046/j.1365-2265.2001.01417.x.
3
Effect of long-term treatment with recombinant human growth hormone on erythropoietin secretion in an anemic patient with panhypopituitarism.重组人生长激素长期治疗对一名全垂体功能减退贫血患者促红细胞生成素分泌的影响。
J Endocrinol Invest. 2000 Jan;23(1):31-6. doi: 10.1007/BF03343673.
4
Human growth hormone and insulin-like growth factor-I inhibit erythropoietin secretion from the kidneys of adult rats.人类生长激素和胰岛素样生长因子-I抑制成年大鼠肾脏分泌促红细胞生成素。
J Endocrinol. 2005 Jan;184(1):199-207. doi: 10.1677/joe.1.05899.
5
Effect of recombinant human GH on circulating granulocyte colony-stimulating factor and neutrophils in patients with adult GH deficiency.
Eur J Endocrinol. 2005 Feb;152(2):211-5. doi: 10.1530/eje.1.01831.
6
Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.持续性非卧床腹膜透析(CAPD)患者在促红细胞生成素治疗前后,生长激素对生长激素释放激素和可乐定的反应。
Nephron. 1996;74(3):548-54. doi: 10.1159/000189450.
7
The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin.重组人促红细胞生成素纠正贫血前后,促肾上腺皮质激素和生长激素释放激素对慢性血液透析患者各自分泌轴的影响。
J Clin Endocrinol Metab. 1994 Jan;78(1):63-9. doi: 10.1210/jcem.78.1.8288716.
8
Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.接受重组人生长激素治疗的成年血液透析患者中的生长激素、胰岛素样生长因子及其结合蛋白
Clin Nephrol. 1999 Aug;52(2):103-9.
9
Short-term recombinant human growth hormone therapy does not modify growth hormone, thyrotropin and prolactin responses to thyrotropin-releasing hormone in adult dialysis patients.短期重组人生长激素治疗不会改变成年透析患者生长激素、促甲状腺激素和催乳素对促甲状腺激素释放激素的反应。
Nephrol Dial Transplant. 2000 Jun;15(6):856-61. doi: 10.1093/ndt/15.6.856.
10
Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.生长激素缺乏症患者连续输注生长激素(GH)与每日注射生长激素4周的比较。
J Clin Endocrinol Metab. 1995 Aug;80(8):2410-8. doi: 10.1210/jcem.80.8.7543114.

引用本文的文献

1
Hydrogen Ion Dynamics as the Fundamental Link between Neurodegenerative Diseases and Cancer: Its Application to the Therapeutics of Neurodegenerative Diseases with Special Emphasis on Multiple Sclerosis.氢离子动力学是神经退行性疾病和癌症之间的基本联系:其在神经退行性疾病治疗中的应用,特别强调多发性硬化症。
Int J Mol Sci. 2022 Feb 23;23(5):2454. doi: 10.3390/ijms23052454.
2
The Role of the Multiple Hormonal Dysregulation in the Onset of "Anemia of Aging": Focus on Testosterone, IGF-1, and Thyroid Hormones.多种激素失调在“衰老性贫血”发病中的作用:聚焦于睾酮、胰岛素样生长因子-1和甲状腺激素。
Int J Endocrinol. 2015;2015:292574. doi: 10.1155/2015/292574. Epub 2015 Dec 8.
3
Effects of growth hormone therapeutic supplementation on hematopoietic stem/progenitor cells in children with growth hormone deficiency: focus on proliferation and differentiation capabilities.
生长激素治疗性补充对生长激素缺乏症儿童造血干细胞/祖细胞的影响:聚焦增殖与分化能力
Endocrine. 2015 Sep;50(1):162-75. doi: 10.1007/s12020-015-0591-0. Epub 2015 Apr 29.
4
OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients.机会:生长激素对血液透析患者结局影响的一项随机临床试验。
Clin J Am Soc Nephrol. 2008 Nov;3(6):1741-51. doi: 10.2215/CJN.02760608.
5
Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial.慢性血液透析患者与匹配的健康受试者相比生长激素的药代动力学和药效学:一项开放、非随机、平行组试验。
Clin Endocrinol (Oxf). 2007 Nov;67(5):776-83. doi: 10.1111/j.1365-2265.2007.02962.x. Epub 2007 Jul 18.
6
Effect of long-term treatment with recombinant human growth hormone on erythropoietin secretion in an anemic patient with panhypopituitarism.重组人生长激素长期治疗对一名全垂体功能减退贫血患者促红细胞生成素分泌的影响。
J Endocrinol Invest. 2000 Jan;23(1):31-6. doi: 10.1007/BF03343673.